The Chronic Hepatitis B Virus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Chronic Hepatitis B Virus Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Hepatitis B Virus Market.

Some of the key takeaways from the Chronic Hepatitis B Virus Pipeline Report:

• Companies across the globe are diligently working toward developing novel Chronic Hepatitis B Virus treatment therapies with a considerable amount of success over the years. 
• Chronic Hepatitis B Virus companies working in the treatment market are Precision Biosciences, Silverback Therapeutics, Vir Biotechnology, Arbutus bio, Dicerna Pharmaceuticals, Roche, Ligand Pharmaceuticals, Dong-A ST Co., and others, are developing therapies for the Chronic Hepatitis B Virus treatment 

• Emerging Chronic Hepatitis B Virus therapies in the different phases of clinical trials are- PBGENE-HBV, SBT8230, VIR-3434, AB 729, RG6346, RG7854, Pradefovir, DA 2802, and others are expected to have a significant impact on the Chronic Hepatitis B Virus market in the coming years.   
• In January 2022, In a second Phase 2a/2b clinical research examining VBI-2601 (BRII-179), an immunotherapeutic candidate that targets chronic hepatitis B virus (HBV), VBI Vaccines reported that the first patient had received a dose.
• In December 2021, In order to develop and market AB-729 for the treatment or prevention of hepatitis B in mainland China, Hong Kong, Macau, and Taiwan, Arbutus Biopharma Corporation and Qilu Pharmaceutical made their partnership and exclusive licencing agreement public.A $40 million upfront payment and up to $245 million in development, regulatory, and sales milestone payments were made by Qilu to Arbutus as per the terms of the contract. Furthermore, Qilu invested $15 million in equity in Arbutus at a cost of $4.19 a share.
• In March 2022, At the 31st Conference of the Asian Pacific Association for the Study of the Liver (APASL) 2022, Brii Biosciences Limited presented fresh findings from a Phase II randomised, double-blind, placebo-controlled trial of BRII-835 (VIR-2218) in Chinese patients with chronic hepatitis B virus (HBV) infection. The data showed that two doses of BRII-835 (VIR-2218), an investigational small interfering ribonucleic acid (siRNA) that mediates RNA interference (RNAi), decreased hepatitis B surface antigen (HBsAg) in Chinese patients with chronic HBV infection. Both HBeAg- and HBeAg+ patients experienced comparable HBsAg decreases. Additionally, there were no clinically significant alanine transaminase (ALT) increases found, and BRII-835 (VIR-2218) was well tolerated with all treatment-emergent adverse events (TEAEs) described as mild or moderate.
• In March 2022, ALG-020572’s development in people with chronic hepatitis B (CHB) has been stopped by Aligos Therapeutics. After one of the patients experienced a major adverse event (SAE) that necessitated a brief hospitalisation, the initial CHB cohort of Study ALG-020572-401 was discontinued.After receiving 210 mg of the medication several times, the patient’s alanine aminotransferase (ALT) level significantly increased. Only one of four chronic hepatitis B (CHB) participants in the sample had the potentially drug-related ALT flares, a sign of liver damage, according to Aligos.
• In October 2021, The clinical collaboration agreement between Antios Therapeutics and Assembly Biosciences will be used to test a triple combination therapy on people with chronic hepatitis B virus (HBV) infection.
• In March 2021, In a Roche-sponsored Phase II combo trial for the treatment of chronic hepatitis B virus (HBV) infection, Dicerna Pharmaceuticals reported that Roche had started RG6346. The efficacy and safety of RG6346 in combination with numerous additional medicines with various modes of action will be assessed in the Phase II platform trial.

Chronic Hepatitis B Virus Overview

The “Hepadnaviridae” family of little DNA viruses includes the hepatitis B virus. It is an HBV-causes liver infection that is prevented by vaccination. Either an acute infection or a chronic infection can occur from a hepatitis B infection. It is known as a “acute infection” when a person first contracts the hepatitis B virus, and the majority of healthy individuals who contract the virus do not experience any symptoms and are able to get rid of it without any issues.

Get a Free Sample PDF Report to know more about Chronic Hepatitis B Virus Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-pipeline-insight

Emerging Chronic Hepatitis B Virus Drugs Under Different Phases of Clinical Development Include:

• PBGENE-HBV: Precision Biosciences
• SBT8230: Silverback Therapeutics
• VIR-3434: Vir Biotechnology
• AB 729: Arbutus bio
• RG6346: Dicerna Pharmaceuticals
• RG7854: Roche
• Pradefovir: Ligand Pharmaceuticals
• DA 2802: Dong-A ST Co.

Chronic Hepatitis B Virus Route of Administration

Chronic Hepatitis B Virus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Chronic Hepatitis B Virus Molecule Type

Chronic Hepatitis B Virus Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Chronic Hepatitis B Virus Pipeline Therapeutics Assessment

• Chronic Hepatitis B Virus Assessment by Product Type
• Chronic Hepatitis B Virus By Stage and Product Type
• Chronic Hepatitis B Virus Assessment by Route of Administration
• Chronic Hepatitis B Virus By Stage and Route of Administration
• Chronic Hepatitis B Virus Assessment by Molecule Type
• Chronic Hepatitis B Virus by Stage and Molecule Type

DelveInsight’s Chronic Hepatitis B Virus Report covers around 55+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Chronic Hepatitis B Virus product details are provided in the report. Download the Chronic Hepatitis B Virus pipeline report to learn more about the emerging Chronic Hepatitis B Virus therapies

Some of the key companies in the Chronic Hepatitis B Virus Therapeutics Market include:

Key companies developing therapies for Chronic Hepatitis B Virus are – Gilead Sciences, Hoffmann-La Roche, Fujian Cosunter Pharmaceutical, Precision Biosciences, Dong-A ST Co., Ltd., Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Dicerna Pharmaceuticals, Yangshengtang Co., Ltd, Altimmune, Beam Therapeutics, SCG Cell Therapy Pte Ltd, Silverback Therapeutics, Bluejay Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, Vir Biotechnology, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharma, ISA Pharmaceuticals, Indaptus Therapeutics, Immunocore,  and others.

Chronic Hepatitis B Virus Pipeline Analysis:

The Chronic Hepatitis B Virus pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Hepatitis B Virus with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Hepatitis B Virus Treatment.
• Chronic Hepatitis B Virus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Hepatitis B Virus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Hepatitis B Virus market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Chronic Hepatitis B Virus drugs and therapies

Chronic Hepatitis B Virus Pipeline Market Drivers

• High prevalence of chronic HBV infection, increasing Research and development in Chronic Hepatitis B are some of the important factors that are fueling the Chronic Hepatitis B Virus Market.

Chronic Hepatitis B Virus Pipeline Market Barriers

• However, high cost of treatment, limited access to the diagnosis of hepatitis B and other factors are creating obstacles in the Chronic Hepatitis B Virus Market growth.

Scope of Chronic Hepatitis B Virus Pipeline Drug Insight    

• Coverage: Global
• Key Chronic Hepatitis B Virus Companies: Precision Biosciences, Silverback Therapeutics, Vir Biotechnology, Arbutus bio, Dicerna Pharmaceuticals, Roche, Ligand Pharmaceuticals, Dong-A ST Co., and others
• Key Chronic Hepatitis B Virus Therapies: PBGENE-HBV, SBT8230, VIR-3434, AB 729, RG6346, RG7854, Pradefovir, DA 2802, and others
• Chronic Hepatitis B Virus Therapeutic Assessment: Chronic Hepatitis B Virus current marketed and Chronic Hepatitis B Virus emerging therapies
• Chronic Hepatitis B Virus Market Dynamics: Chronic Hepatitis B Virus market drivers and Chronic Hepatitis B Virus market barriers 

Request for Sample PDF Report for Chronic Hepatitis B Virus Pipeline Assessment and clinical trials

Table of Contents 

1. Chronic Hepatitis B Virus Report Introduction

2. Chronic Hepatitis B Virus Executive Summary

3. Chronic Hepatitis B Virus Overview

4. Chronic Hepatitis B Virus- Analytical Perspective In-depth Commercial Assessment

5. Chronic Hepatitis B Virus Pipeline Therapeutics

6. Chronic Hepatitis B Virus Late Stage Products (Phase II/III)

7. Chronic Hepatitis B Virus Mid Stage Products (Phase II)

8. Chronic Hepatitis B Virus Early Stage Products (Phase I)

9. Chronic Hepatitis B Virus Preclinical Stage Products

10. Chronic Hepatitis B Virus Therapeutics Assessment

11. Chronic Hepatitis B Virus Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Chronic Hepatitis B Virus Key Companies

14. Chronic Hepatitis B Virus Key Products

15. Chronic Hepatitis B Virus Unmet Needs

16 . Chronic Hepatitis B Virus Market Drivers and Barriers

17. Chronic Hepatitis B Virus Future Perspectives and Conclusion

18. Chronic Hepatitis B Virus Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services